Review Article

Cystic fibrosis–related dyslipidemia*

Dislipidemia relacionada à fibrose cística

Crésio de Aragão Dantas Alves¹, Daniela Seabra Lima²

Abstract

This article aims to review the physiopathology, diagnosis and treatment of cystic fibrosis–related dyslipidemia (CFD). Bibliographic searches of the Medline and Latin American and Caribbean Health Sciences Literature databases were made (year range, 1987–2007), and the most representative papers on the theme were selected. The characteristic symptoms of CFD are hypertriglyceridemia—with or without hypocholesterolemia—and essential fatty acid deficiency. The principal CFD risk factors are pancreatic insufficiency, high-carbohydrate diet, liver diseases, inflammatory state and corticosteroid therapy. There are no specific recommendations regarding screening, which is typically performed based on the diagnosis, and at regular intervals, and more frequently in individuals belonging to high-risk groups. Treatment includes a balanced diet, micronutrient supplementation, and regular physical exercise according to individual tolerance. We conclude that there are few articles in the literature regarding the frequency, etiology and management of CFD. Preventive and therapeutic recommendations for hypertriglyceridemia are extrapolated from studies in individuals without cystic fibrosis. Further research is necessary to investigate the association of essential fatty acid deficiency and the physiopathology of cystic fibrosis. Since hypertriglyceridemia is an important risk factor for coronary artery disease, prospective studies will contribute for a better understanding of the natural history of this condition and define how to prevent and treat it.

Keywords: Cystic fibrosis; Dyslipidemias; Hypertriglyceridemia; Fatty Acids, nonesterified.

Introduction

Cystic fibrosis (FC) is a multisystemic hereditary disorder primarily characterized by exocrine pancreatic insufficiency, obstruction and infection of the airways.⁴ Clinical manifestations can be explained, for the most part, by the chronic inflammation and by the dysfunction of the cystic fibrosis transmembrane regulator protein (CFTR), with malfunctioning of the chloride channel.⁵ Among the many mutations described in the CF gene, the most frequently found is ΔF508.⁶

As a result of the increases in life expectancy due to the advancements in treatment, some complications unobserved before have begun to be diagnosed, such as

* Study carried out in the Department of Pediatric Endocrinology, Universidade Federal da Bahia – UFBA, Federal University of Bahia – School of Medicine Professor Edgard Santos University Hospital, Salvador, Brazil.
1. Coordinator of Medical Residence in Pediatric Endocrinology. Universidade Federal da Bahia – UFBA, Federal University of Bahia – School of Medicine, Salvador, Brazil.
2. Third-Year Resident in Pediatric Endocrinology. Universidade Federal da Bahia – UFBA, Federal University of Bahia – School of Medicine, Salvador, Brazil.
Correspondence to: Crésio Alves. Rua Plínio Moscoco, 222/601, CEP 40157-190, Salvador, BA, Brazil.
Tel 55 71 3357-5500. E-mail: cresio.alves@uol.com.br
Financial Support: None.
diabetes mellitus, liver disease, osteoporosis and, more recently, dyslipidemia. Some individuals with CF present a dyslipidemic pattern characterized by hypertriglyceridemia with or without hypocholesterolemia. The most frequently observed alteration is hypertriglyceridemia, although these patients have an increase in energy expenditure, poor intestinal absorption of fat and reduction in food intake. Although hypertriglyceridemia is one of the risk factors for atherosclerotic cardiovascular disease, little attention has been given to the impact of this complication in the morbidity of patients with CF. This fact becomes more relevant when there is an association with CF-related diabetes mellitus, since hyperglycemia contributes to the atherogenesis through glycation and peroxidation of the low-density lipoprotein (LDL).

Due to the lack of studies on the theme, the objective of the present article is to conduct a critical review on the current knowledge of physiopathology, diagnosis and approach of dyslipidemia in patients with CF. In the present study, this complication was named cystic fibrosis-related dyslipidemia (CFD). Medline and the Latin American and Caribbean Health Sciences Literature databases were used in the bibliographic search, selecting the most relevant articles on the theme published in the period of 1987 to 2007.

**Normal lipid metabolism**

Cholesterol and triglycerides (TG; or triacylglycerol) are the principal plasma lipids. Cholesterol is fundamental for the synthesis of steroid hormones, synthesis of bile acids and formation of cell membranes. The TGs are the principal energy reserve of the body. Essential fatty acids (for instance, linoleic and linolenic), participate in the development and functioning of the central nervous system, immune system and vascular function. However, since these are inadequately produced by the mammal cells, maintenance of their serum levels depends on adequate intake and absorption.

Since they are practically insoluble in water, cholesterol and TG are transported in plasma associated with proteins, forming soluble complexes named lipoproteins. Lipoproteins have spherical form and are formed by the nucleus and by the external layer. The nucleus contains principally cholesterol and TG esters. The external layer is composed of phospholipids and free cholesterol. On the surface, there are apoproteins or apolipoproteins, which bind to specific receptors of the cell responsible for the metabolism of lipoproteins.

Lipoproteins are classified according to their electrophoretic mobility and density (the greater the quantity of apoproteins, the greater the density, and the greater the quantity of TG, the lower the density). The principal lipoproteins are the following: chylomicrons (CM), very low-density lipoprotein (VLDL), intermediate density lipoprotein, low-density lipoprotein (LDL) and high-density lipoprotein (HDL). Table 1 shows the properties of the principal lipoproteins.

In the intestine, the cholesterol and TG of the diet are emulsified by bile acids and hydrolyzed by pancreatic lipase. TGs are broken into fatty acids and monoglycerides, and the esters of cholesterol in fatty acids and non-esterified cholesterol. In the intestinal cell, the monoglycerides are re-esterified in TG and stored in the CMs. The ApoC-II, ApoB-48 and Apo-E are the principal apolipoproteins of the

---

**Table 1 - Properties of the principal lipoproteins.**

<table>
<thead>
<tr>
<th>Properties</th>
<th>Chylomicrons</th>
<th>VLDL</th>
<th>LDL</th>
<th>HDL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Composition (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cholesterol</td>
<td>3</td>
<td>22</td>
<td>50</td>
<td>20</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>90</td>
<td>55</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Phospholipids</td>
<td>6</td>
<td>15</td>
<td>25</td>
<td>25</td>
</tr>
<tr>
<td>Proteins</td>
<td>1</td>
<td>8</td>
<td>20</td>
<td>50</td>
</tr>
<tr>
<td>Origin</td>
<td>Intestine</td>
<td>Liver, intestine</td>
<td>Product of VLDL metabolism</td>
<td>Liver, intestine</td>
</tr>
<tr>
<td>Function</td>
<td>Transports triglycerides from diet</td>
<td>Transports hepatic triglycerides</td>
<td>Supplies TC to cells</td>
<td>Performs TC reverse transport</td>
</tr>
</tbody>
</table>

VLDL: very low-density lipoprotein; LDL: low-density lipoprotein; HDL: high-density lipoprotein; and TC: total cholesterol.
Carbohydrate-rich, low-fat diet

Patients with exogenous pancreatic insufficiency and inadequate enzymatic replacement do not tolerate diets with normal fat level due to poor intestinal absorption, and, as a defense mechanism, consume an excessive amount of carbohydrates.\(^{5,13}\) The consumption of these low-fat carbohydrate-rich diets can be one of the causes of the hypertriglyceridemia related to CF. In these cases, the excessive and chronic consumption of carbohydrates makes the liver exceed its capacity of synthesis and storage of glycogen, deviating the metabolic access to the production of TG.\(^{14}\) Other explanations would be the decrease of the activity of the lipoprotein lipase and the increase of the intestinal absorption of glucose.\(^{15}\)

Fat-rich diet

In order to study the repercussion of a fat-rich diet on the serum lipids, a study compared the lipid profile of adults with CF, with and without exogenous pancreatic insufficiency, with healthy controls.\(^{16}\) It was observed that patients with CF and pancreatic insufficiency, despite consuming great quantities of fat and cholesterol, presented no worsening in the lipid profile, in contrast to those without exogenous pancreatic insufficiency, in which the same atherogenic risk of the general population was observed. That is, CF patients with normal exogenous pancreatic function present elevated risk of atherogenesis, similar to the general population, when consuming fat-rich diets. However, this hypothesis has been controversial since a study in which no significant difference in the lipid profile of patients with CF was observed when compared to the control group, despite the use of a fat-rich diet,\(^{17}\) and in another study it was reported that, even with enzymatic supplementation, the absorption of the fat of the diet varied 79–93%\(^{18}\).

Hepatic dysfunction

Liver disease is considered a serious comorbidity of the CF, altering its prognosis and the life quality.\(^{19}\) The prevalence depends on the criteria used: from 1.4–7% by clinical evaluation, to more than 20% if biochemical and ultrasonographic methods are used.\(^{19}\) Liver disease results from the hepatic steatosis, which is usually attributed to the accumulation of
TG and LDL in the hepatic parenchyma due to the reduction in the synthesis of apolipoproteins and, in some cases, due to carnitine deficiency. Depending on its severity, the liver disease can contribute to the hypertriglyceridemia.

**Use of corticosteroids**

Corticosteroids are one of the most relevant causes of secondary dyslipidemia, principally of hypertriglyceridemia. As patients with CF, principally those with pulmonary complications, use these medications frequently or chronically, this can be, theoretically, one more factor contributing to dyslipidemia. However, no studies showing this association in patients with CF were found in the literature.

**Lipoprotein alterations in cystic fibrosis**

**Quantitative alterations**

The principal quantitative alterations of the lipid metabolism in CF are hypertriglyceridemia and hypocholesterolemia. In patients with CF in the United States, in the 5 to 19-year age bracket, the mean serum cholesterol was 133 ± 30 mg/dL and that of TG was 126 ± 70 mg/dL in comparison with, respectively, 149 mg/dL and 55 mg/dL for the population of the same age and gender without CF. In the 20 to 44-year age bracket, the mean values for total cholesterol (TC) and TG were 155 ± 39 mg/dL and 162 ± 118 mg/dL, when compared, respectively, with 199 mg/dL and 87 mg/dL for the control group. This fact reinforces the information that CF patients present, on average, lower cholesterol values, and higher TG values in relation to their population mean. In the same study, hypertriglyceridemia defined by values above 200 mg/dL was found in only 16% of the patients.

**Qualitative alterations**

Approximately 85% of the patients with CF present essential fatty acid deficiency. The typical profile of this deficiency is characterized by the decrease of the concentration of linoleic (18:2n-6) and docosahexaenoic acids (22:6n-3); and increase of the eicosatrienoic acid (20:3n-9), oleic acid (18:1n-9) and palmitoleic acid (16:1n-7). As these alterations were also detected in well-nourished patients with CF and without exogenous pancreatic insufficiency and in their parents, this fact suggests that there can be a defect in the

---

832 Alves CAD, Lima DS

J Bras Pneumol. 2008;34(10):829-837
metabolism of fatty acids related to the etiology of CF, as, for instance, increase in their oxidation as a source of energy, use as precursors of the inflammatory response, defective metabolism and alterations of the CFTR. How this profile of fatty acids is related to hypcholesterolemia and hypertriglyceridemia in patients with CF is unknown yet.

**Essential fatty acids deficiency and inflammation in cystic fibrosis**

Morbidity and mortality in patients with CF is largely a result of pulmonary disease, which, in turn, is characterized by the increase of the inflammatory response mediated by pro-inflammatory neutrophils, lymphocytes and cytokines. Patients with CF present increase of the concentration of arachidonic acid and decrease of the concentration of the docosahexaenoic acid. The arachidonic acid is a substrate for the synthesis of prostaglandin E2, thromboxane A2 and leukotriene B4, thus contributing to the inflammatory process typical of the disease. The docosahexaenoic acid is converted in potent anti-inflammatory mediators, so that the reduction of its serum levels is able to contribute to increase of the inflammatory response. In addition, the alterations of the essential fatty acids in the CF can cause decrease of the expression and activity of the peroxisome proliferator-activated receptor alpha (PPAR-α) in lymphocytes. As the PPAR-α presents anti-inflammatory activity, its decrease, in patients with CF, could be another mechanism responsible for the exacerbated inflammatory response. This observation is important since it can lead to researches which use fibrates and glitazone, synthetic activators of the PPAR-α, in the treatment of CF.

Therefore, in case it is possible to correlate the serum levels of the essential fatty acids with their tissue concentration, perhaps the attempt to normalize those with the objective of attenuating the chronic inflammatory response is reasonable. Corroborating these data, a study showed that the levels of fatty acids increased in patients with CF after treatment with antibiotics, and in another study improvement of the inflammatory response in mice chronically infected by *Pseudomonas aeruginosa* was reported after supplementation with omega-6 fatty acids.

**Dyslipidemia and cardiovascular risk in the cystic fibrosis**

The role of the hypertriglyceridemia as an independent risk factor for the cardiovascular disease is still unclear. In individuals without CF, this risk would be increased in situations in which the hypertriglyceridemia associates with the presence of smaller and cholesterol-rich VLDL fractions (for instance, diabetes mellitus, obesity and metabolic syndrome); and would be inexistent in hypertriglyceridemias accompanied by large and TG-rich VLDL fractions (for instance, carbohydrate-rich diets and excessive alcohol intake).

As patients with CF and hypertriglyceridemia presented no atherogenic risk factors (for instance, obesity, metabolic syndrome), except for the presence of diabetes mellitus in some cases, and as the carbohydrate-rich diet does not associate with a greater risk of cardiovascular disease, it becomes even more difficult to evaluate the cardiovascular repercussion of CFD. A recent epidemiologic study showed, in the population in general, the existence of a moderate but rather significant association between elevated levels of TG and the increased risk of coronary disease. This fact calls attention to the need to evaluate such risk in patients with CF and hypertriglyceridemia.

**Approach to cystic fibrosis-related dyslipidemia**

**Screening and diagnosis**

There is no specific recommendation for screening and laboratory testing diagnosis of CFD. Therefore, the orientations and reference values are extrapolated from the guidelines of the National Cholesterol Education Program, 1992 and from the Brazilian Cardiology Society, 2005 for children and from the recommendations of the Adult Panel III of the National Cholesterol Education Program (Table 3) for adults. The reference values suggested by the Brazilian Cardiology Society for individuals aged less than 19 years differ from those of the National Cholesterol Education Program, since it proposes lower values of CT, LDL and TG.

Dyslipidemia screening is carried out through the determination of the lipid profile (CT, HDL, VLDL and TG) after a 12-hour fast. The LDL is calculated using...
the Friedewald formula \( \text{LDL} = \left[ \text{CT} - \text{HDL} \right] - \left[ \text{TG}/5 \right] \) if TGs < 400 mg/dL. Ideally, the lipid profile should be determined in individuals using their habitual diet, in absence of great recent variations in weight and without having performed vigorous physical activity or having consumed alcohol within 24 hours preceding the examination. The use of medications which alter the lipid profile such as corticosteroids, hormonal contraceptives, antihypertensives and anticonvulsants should be questioned, as well as the traditional risk factors for dyslipidemia such as smoking, hypertension and sedentary life style, among others.[2,6]

Abnormal results should be confirmed by a second examination. If altered test results persist, it is fundamental to exclude and treat secondary causes such as hypothyroidism, diabetes, kidney disease, sedentary life style, consumption of alcohol and use of medicaments, principally corticosteroids and estrogens.[2,6]

Despite the frequent reports of essential fatty acids deficiency, principally the linoleic and the docosahexaenoic, there are no recommendations as to routine doses of the free fatty acids in the blood or in the membranes of the erythrocytes of the patients with CF.[30] Some of the factors which make the establishment of a normality value more difficult are: infections (decreasing the levels of free fatty acids), nutritional status, severity of the mutation of the CFTR and the fact that the serum levels of fatty acids do not reflect their tissue concentration.[25,27,29]

**Treatment**

*Non-pharmacological treatment*

Due to the greater metabolic necessity as a result of the elevated baseline energy expenditure, loss of fat due to poor intestinal absorption of fats and reduction of food intake, especially during episodes of infection, patients with CF are advised to use balanced high-protein and high-caloric diet, (120-150% of the traditional daily recommendations), with supplementation of micronutrients according to their specific deficiencies and replacement of liposoluble vitamins, as well as fibers.[2,6]

In the absence of exogenous pancreatic insufficiency, the energy recommendation should be similar to that of the population without CF, therefore the use of high-caloric diet with high level of lipids should be monitored due to the risk of dyslipidemia.[16] If there is exogenous pancreatic insufficiency, enzymatic supplementation is necessary. Normalization of fat in the stool should not be expected, since the use of excessive doses of enzymes brings no greater benefits and can cause damage to the structure of the intestine leading to a fibrosing colonopathy.[6,18] The maximum dose of pancreatic enzymes should not exceed 10,000 IU of lipase/kg/day.[39]

In patients without CF, dietetic recommendations for the treatment of hypertriglyceridemia include restriction to saturated and trans fat and increase in the consumption of omega-3 fatty acids.[26] The restriction of fats to less than 30% of the total energy consumption does not apply to CF, since the fat represents 31-35% of the caloric intake provided that, even with the pancreatic enzymes replacement, 5-20% of the fat of the diet is not absorbed.[18] In one study,[40] a greater intake of saturated and monosaturated fat and lesser intake of polyunsaturated fat has been reported in patients with CF when compared to the controls, drawing attention to the necessity of balancing the intake of fat in these patients, in order to minimize the deficiency of essential fatty acids.

**Table 2** - Reference values for the lipid profile for individual aged less than 20 years according to the National Cholesterol Education Program (1992) and the Brazilian Cardiology Society (2005).

<table>
<thead>
<tr>
<th>Lipid</th>
<th>Desired value(a)</th>
<th>Borderline value(a)</th>
<th>Undesired value(a)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NCEP</td>
<td>BCS</td>
<td>NCEP</td>
</tr>
<tr>
<td>TC</td>
<td>&lt;170</td>
<td>&lt;150</td>
<td>170-199</td>
</tr>
<tr>
<td>LDL</td>
<td>&lt;110</td>
<td>&lt;100</td>
<td>110-129</td>
</tr>
<tr>
<td>HDL</td>
<td>&gt;45</td>
<td>≥45</td>
<td>35-45</td>
</tr>
<tr>
<td>VLDL</td>
<td>Up to 23</td>
<td>Up to 23</td>
<td>-</td>
</tr>
<tr>
<td>TG</td>
<td>&lt;125</td>
<td>&lt;100</td>
<td>-</td>
</tr>
</tbody>
</table>

\(a\)Values expressed in mg/dL. NCEP: National Cholesterol Education Program; BCS: Brazilian Cardiology Society; TC: total cholesterol; LDL: low-density lipoprotein; HDL: high-density lipoprotein; VLDL: very low-density lipoprotein; and TG: triglycerides.
Some studies have been carried out with ursodeoxycholic acid with the objective of improving bile flow and thus prevent or treat liver disease related to CF and therefore, reduce the risk of dyslipidemia. However, in one study, no significant evidence of improvement of the hepatic function were observed with the use of such medication.

The use of supplementation with omega-3 and omega-6 fatty acids has presented conflicting results, the conduction of further studies being necessary for the recommendation of its use in the treatment of CF.

Final considerations and perspectives for the future

There are few studies evaluating the prevalence and physiopathology of CFD. Therefore, there are no consensuses orienting on how to perform the screening for this disorder, how to prevent it and, if present, how to treat it. Due to the increase in life expectancy of the cystic-fibrotic patients and in view of the metabolic alterations presented by these individuals, it is fundamental that the conduction of prospective studies aiming to answer most of these questions, principally the role of the hypertriglyceridemia in isolation as a risk factor for cardiovascular diseases. To date, most recommendations as for the management of hypertriglyceridemia come from studies in patients without CF and with other cardiovascular risk factors. More studies aiming to better clarify the role of the deficiency of essential fatty acids in the physiopathology of the CF are also necessary.

References


